Insights
Search Results
Client Highlights
3.06.26
Wilson Sonsini Advises Cognito Therapeutics on Oversubscribed $105 Million Series C
On March 5, 2026, Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, announced the closing of an oversubscribed $105 million Series C financing round. Wilson Sonsini Goodrich & Rosati advised Cognito Therapeutics on the transaction.
Client Highlights
3.03.26
Wilson Sonsini Advises Versori on Acquisition by Avalara
On February 27, 2026, Avalara, the leading provider of cloud-based tax compliance automation software, announced that it acquired Versori Group, an integration platform company specializing in automated connector development powered by agentic AI. Wilson Sonsini Goodrich & Rosati advised Versori on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Quantum Computing on $110 Million Acquisition of Luminar Semiconductor
On December 15, 2025, Quantum Computing (QCi), an innovative, quantum optics and integrated photonics technology company, announced that it has signed an agreement to acquire Luminar Semiconductor (LSI), a wholly owned subsidiary of Luminar Technologies, in an all-cash transaction valued at $110 million, subject to customary adjustments. Wilson Sonsini Goodrich & Rosati is advising QCi on the transaction
Client Highlights
11.06.25
Wilson Sonsini Advises Azalea Therapeutics on $82 Million Financing
On November 4, 2025, Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The funding was led by Third Rock Ventures, with participation from RA Capital Management, Yosemite, Sozo Ventures, and select individual investors. Wilson Sonsini Goodrich & Rosati advised Azalea Therapeutics on the transaction.
Client Highlights
10.02.25
Wilson Sonsini Advises BeSound on $6.8 Million Financing
On September 30, 2025, BLOCH Quantum Imaging Solutions, Inc. (dba BeSound), a pioneering healthcare technology company revolutionizing breast cancer detection, announced it has raised $6.8 million from investors, including Overwater Ventures, Kindred Ventures, Muse Capital, Lux Capital, Wisdom.VC, Retron VC, Mana Ventures, Pave Health Ventures, SSC Venture Partners, Hyperplane VC, and Tom Hale, the CEO of Oura. Wilson Sonsini Goodrich & Rosati advised BeSound on the transaction.
Client Highlights
4.09.25
Wilson Sonsini Advises TigaTx on Acquisition by Epsilogen
On April 7, 2025, Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibody therapeutics, announced that it has completed the acquisition of TigaTx, a Boston-based biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading pan-isotype cancer antibody company.
Client Highlights
1.10.25
Wilson Sonsini Advises Prudentia Sciences on $7 Million Funding as Company Emerges from Stealth
On January 9, 2025, Prudentia Sciences, an AI-powered technology platform for life sciences, emerged from stealth supported by $7 million in funding. Google Ventures led the financing with participation from Iaso Ventures and Virtue. Wilson Sonsini Goodrich & Rosati advised Prudentia Sciences on the transaction.
Client Highlights
9.19.24
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A
On September 19, 2024, GC Therapeutics (GCTx), a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines, launched and announced the successful completion of a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC, bringing the total capital raised by GCTx to $75 million. Wilson Sonsini Goodrich & Rosati advised GC Therapeutics on the transaction.
Client Highlights
8.15.23
Wilson Sonsini Advises Amber Bio on $26 Million Seed Financing
On August 3, 2023, Amber Bio, a biotechnology company pioneering multi-kilobase gene editing platforms to reach previously undruggable diseases, announced $26 million in seed funding co-led by Playground Global and Andreessen Horowitz Bio + Health with participation from Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC. Wilson Sonsini Goodrich & Rosati advised Amber Bio on the transaction.
Client Highlights
6.28.23
Wilson Sonsini Advises Nohbo on Series A Funding
On June 5, 2023, Florida-based Nohbo, a leader in the development of groundbreaking water-soluble packaging technologies, announced the completion of its Series A funding round, led by Material Impact Fund. While the financial details remain undisclosed, the round includes participation from Dara Holdings, Susquehanna Private Equity Investments, LLLP, and SaferMade. The funds will bolster Nohbo's growth within the hospitality sector and expedite the widespread adoption of its patented technology. Wilson Sonsini Goodrich & Rosati advised Nohbo on the transaction.
Client Highlights
6.21.23
Wilson Sonsini Advises Delve Bio on Licensing from UCSF, Launch, and $35 Million Series A Financing
On June 20, 2023, Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, debuted with $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) – and joined by Section 32 and GV. The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests. Delve Bio was started in connection with UCSF through its engagement and opportunity development team in Innovation Ventures’ Office of Technology Management and Advancement (OTMA), which leads licensing, start-up, and business development efforts on behalf of the university. The company holds an exclusive in-license from UCSF for the development and commercialization of its mNGS diagnostic platform, including its clinically validated mNGS test for cerebrospinal fluid that has been widely used by clinicians to solve complex cases of meningitis and encephalitis.
Client Highlights
9.21.22
Wilson Sonsini Advises Investor Time BioVentures on Phantom Neuro’s $6 Million Seed Funding Round
On September 12, 2022, Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, announced a $6 million funding round led by new investor Time BioVentures. The round included participation from another new investor, Risk & Return (R²), an innovative venture fund focused on "capitalism for good". Wilson Sonsini Goodrich & Rosati advised Time BioVentures on the transaction.